Two is company, is three a crowd? Triplet therapy, novel molecular targets, and updates on the management of advanced renal cell carcinoma

Goodstein, T., Yang, Y., Runcie, K., Srinivasan, R., & Singer, E. A. (2023). Two is company, is three a crowd? Triplet therapy, novel molecular targets, and updates on the management of advanced renal cell carcinoma. Current Opinion in Oncology, 35(3), 206–217. https://doi.org/10.1097/cco.0000000000000939

Authors:

Taylor Goodstein

Yuanquan Yang

Karie Runcie

Ramaprasad Srinivasan

Eric A Singer

Affiliated Authors:

Karie Runcie

Columbia Affiliation: